CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients.

Yanwei Zhang,Baohui Han,Jialin Qian,Yuqing Lou,Jun Lu,Minjuan Hu,Xueyan Zhang,Huimin Wang,Beibei Sun,Tianqing Chu

doi:10.3389/fonc.2020.01049

Abstract

Background: This study was performed to evaluate the value of inflammatory biomarkers in predicting the prognosis of early-stage (stage IA-IIB) lung adenocarcinoma.Methods: Ten inflammatory biomarkers were tested with a Luminex bead-based assay in early-stage lung adenocarcinoma patients who underwent resection.Results: A total of 152 early-stage lung adenocarcinoma patients were analyzed in this study. The mean patient age (SD) was 59.9 (9.4) years. In total, 58.6% of patients were females, and never smokers accounted for 84.0%. Lung adenocarcinoma patients with high CXCL9 levels had a 71% reduced risk of recurrence relative to patients with low CXCL9 levels (HR = 0.29, 95% CI: 0.13–0.64, p = 0.0021). After Bonferroni correction, CXCL9 remained significantly related to the risk of early-stage lung adenocarcinoma recurrence. Lung adenocarcinoma patients with high CXCL9 levels had an 80% reduced risk of death relative to patients with low CXCL9 levels (HR = 0.20, 95% CI: 0.05–0.78, p = 0.021), and those in the TCGA validation cohort were at a 29% reduced risk of death (HR = 0.71, 95% CI: 0.45–0.99, p = 0.044).Conclusion: Our results demonstrate for the first time that the CXCL9 level is a protective factor for both disease-free survival (DFS) and overall survival (OS) in early-stage lung adenocarcinoma patients.

Highlights

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and is the leading cause of death from cancer worldwide [1]
One of our previous studies evaluated the relationship between 10 inflammatory markers and early-stage lung adenocarcinoma risk [12], and the results showed that four inflammatory markers were significantly associated with the risk of
HR, hazard ratio; 95% CI, 95% confidence interval. *P was adjusted for age, gender, smoking, TNM stage, and adjuvant therapy under multivariate Cox proportional hazards model

Summary

Introduction

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and is the leading cause of death from cancer worldwide [1]. Lung cancer patients diagnosed in the early stages have a good prognosis, but approximately 30–55% of patients develop recurrence despite resection [5]. The identification of biomarkers able to predict which early-stage patients have a high risk for recurrence and death in subsequent years is urgently needed. One of our previous studies evaluated the relationship between 10 inflammatory markers and early-stage lung adenocarcinoma risk [12], and the results showed that four inflammatory markers were significantly associated with the risk of CXCL9 and Prognosis of Lung Adenocarcinoma early-stage lung adenocarcinoma: CXCL13 (C-X-C motif chemokine ligand 13), CCL22 (C-C motif chemokine ligand 22), CXCL9 (C-X-C motif chemokine ligand 9), and IL-10 (interleukin 10). After Bonferroni correction, only CXCL13 and CCL22 were found to be independently related to the risk of early-stage lung adenocarcinoma. This study was performed to evaluate the value of inflammatory biomarkers in predicting the prognosis of early-stage (stage IA-IIB) lung adenocarcinoma

Methods

Results

Conclusion